Healthpoint Biotherapeutics today announced the company has entered into a distribution agreement with Efe Consultoria & Importação Ltda to commercialize the OASIS® Extracellular Matrix product line in Brazil. OASIS® products are based on an extracellular matrix material derived from porcine small intestinal submucosa (SIS®), which is designed to support the body’s natural healing mechanisms in difficult-to-heal and chronic wounds. Both single and bi-layered versions of OASIS® Extracellular Matrix will be marketed in Brazil.
Wed, 06/06/2012
|
||
|
Thu, 01/26/2012
Healthpoint Biotherapeutics today advised that the Centers for Medicare and Medicaid Services (CMS) has eliminated the physician 90-day global surgical period for the application of all skin and dermal substitutes, including OASIS® Wound Matrix and OASIS® Ultra Tri-Layer Matrix. Additionally, the American Medical Association has created eight new CPT® codes that apply to brands in the skin substitute category, resulting in the same Medicare allowable rates for the application of all covered brands of skin and dermal substitutes. |
||
|
Thu, 01/05/2012
Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 9th, at 9:30 am (PST) at the Westin St. Francis Hotel in San Francisco, CA. |
||
|
Tue, 09/13/2011
Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming UBS Global Life Sciences Conference. The presentation is scheduled for the opening day of the conference, Monday, September 19th, at 3 pm (EDT) at the Grand Hyatt in New York City. |
||
|
Thu, 08/04/2011
Healthpoint Biotherapeutics today announced positive topline results for its Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. Robert Kirsner, MD, PhD, will present the topline results of the study on August 4, 2011, from 1:30-2:00 pm, during the opening day of the inaugural meeting of the American College of Wound Healing and Tissue Repair held at The University of Illinois at Chicago. |
